| GENMAB AS DK 1 | 299.200 / -0.27% |
| Date/Time | 05/12 / 21:05 |
| Chg. / Chg.(%) | -0.800 / -0.27% |
| Bid | 298.800 / 20 |
| Ask | 300.700 / 20 |
| Open | 300.500 |
| Previous Close | 300.000 |
| High | 301.600 |
| Low | 299.200 |
| Volume [EUR] | 6,601.200 |
| Volume [Units] | 22 |
| Price fixings | 4 |
| ISIN | DK0010272202 |
| Security | GE9 |
| Exchange | TradeGate |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| OMX Nordic | 2,231.00 |  |
139,142 |
| London Inter.. | 2,229.0 | |
44,819 |
| Cboe Europe .. | 2,230.00 | |
26,191 |
| Turquoise | 2,231.00 | |
8,762 |
| Nasdaq Other.. | 367.4200 | |
321 |
| Stuttgart | 302.200 |  |
150 |
| TradeGate | 299.200 | |
22 |
| Cboe Europe .. | 2,252.00 | |
4 |
| Frankfurt | 300.7000 | |
4 |
| Vienna Globa.. | 299.90 | |
0 |
| München | 306.30 | |
0 |
| Düsseldorf | 300.20 | |
0 |
| Berlin | 301.20 | |
0 |
| Lang & Schwa.. | 297.70 | |
|
| gettex | 301.900 | |
|
| Cboe Europe .. | 2,226.00 | 725 | |
| Mexico | 7,638.15 |  |
11,330 |
News
- Genmab Announces Financial Results for the First Quarter of 2021
05/05/2021 / 17:01 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
04/20/2021 / 12:34 - GlobeNewswire - Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/25/2021 / 20:53 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.